DE60117541D1 - Candesartan zur Behandlung von Migräne - Google Patents
Candesartan zur Behandlung von MigräneInfo
- Publication number
- DE60117541D1 DE60117541D1 DE60117541T DE60117541T DE60117541D1 DE 60117541 D1 DE60117541 D1 DE 60117541D1 DE 60117541 T DE60117541 T DE 60117541T DE 60117541 T DE60117541 T DE 60117541T DE 60117541 D1 DE60117541 D1 DE 60117541D1
- Authority
- DE
- Germany
- Prior art keywords
- treatment
- migraine
- vascular headache
- candesartan
- condition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0002353 | 2000-06-22 | ||
SE0002353A SE0002353D0 (sv) | 2000-06-22 | 2000-06-22 | New use |
PCT/SE2001/001379 WO2001097807A1 (en) | 2000-06-22 | 2001-06-15 | New use of angiotensin ii antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60117541D1 true DE60117541D1 (de) | 2006-04-27 |
DE60117541T2 DE60117541T2 (de) | 2006-09-14 |
Family
ID=20280208
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60117541T Expired - Lifetime DE60117541T2 (de) | 2000-06-22 | 2001-06-15 | Candesartan zur Behandlung von Migräne |
Country Status (21)
Country | Link |
---|---|
US (1) | US7872035B2 (de) |
EP (2) | EP1307192B1 (de) |
JP (1) | JP2003535897A (de) |
KR (1) | KR100692235B1 (de) |
CN (2) | CN1250218C (de) |
AT (1) | ATE318597T1 (de) |
AU (2) | AU2001274765B2 (de) |
BR (1) | BR0111900A (de) |
CA (1) | CA2411553A1 (de) |
DE (1) | DE60117541T2 (de) |
DK (1) | DK1307192T3 (de) |
ES (1) | ES2257416T3 (de) |
HK (1) | HK1053609A1 (de) |
IL (2) | IL153158A0 (de) |
MX (1) | MXPA02012574A (de) |
NO (1) | NO330300B1 (de) |
NZ (1) | NZ523048A (de) |
PT (1) | PT1307192E (de) |
SE (1) | SE0002353D0 (de) |
WO (1) | WO2001097807A1 (de) |
ZA (1) | ZA200209902B (de) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2436361C (en) * | 2001-01-29 | 2010-11-02 | Takeda Chemical Industries, Ltd. | Angiotensin ii antagonistic compound for use as analgesic and antiinflammatory agent |
US20050065094A1 (en) * | 2003-09-05 | 2005-03-24 | Boehringer Ingelheim International Gmbh | Use of telmisartan for the prevention and treatment of vascular headache |
FR2892803B1 (fr) | 2005-10-28 | 2008-04-04 | Valeo Systemes Thermiques | Boite collectrice pour echangeur de chaleur, notamment pour evaporateur de climatisation, echangeur comportant une telle boite |
JP5468420B2 (ja) * | 2010-03-04 | 2014-04-09 | 株式会社マキタ | 手持ち式切断工具 |
WO2012135597A2 (en) | 2011-03-30 | 2012-10-04 | The Johns Hopkins University | Novel, protective, anti-inflammatory receptor and its use in preservation of mitochondrial function, wound healing and repair |
KR20130074808A (ko) | 2011-12-16 | 2013-07-05 | 한올바이오파마주식회사 | 스타틴계 지질저하제에 의한 근육계 부작용의 치료 또는 예방을 위한 로사르탄을 포함하는 약제학적 조성물 |
TWI754772B (zh) * | 2017-09-06 | 2022-02-11 | 美商美國禮來大藥廠 | 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5196444A (en) * | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
US5703110A (en) * | 1990-04-27 | 1997-12-30 | Takeda Chemical Industries, Ltd. | Benzimidazole derivatives, their production and use |
US5241009A (en) | 1990-05-07 | 1993-08-31 | Kimberly-Clark Corporation | Polymeric composition containing carboxy nueutralized with lithium or potassium |
CA2041763A1 (en) * | 1990-05-11 | 1991-11-12 | Sheih-Shung T. Chen | Microbial transformation process for antihypertensive products |
US5128327A (en) * | 1991-03-25 | 1992-07-07 | Merck & Co., Inc. | Angiotensin II antagonists incorporating a nitrogen containing six membered ring heterocycle |
US5177074A (en) * | 1991-03-26 | 1993-01-05 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted thiophene or furan |
US5214153A (en) * | 1992-04-23 | 1993-05-25 | Merck & Co., Inc. | Actinoplanes transformation process anti-hypertensive compound and method of use thereas |
-
2000
- 2000-06-22 SE SE0002353A patent/SE0002353D0/xx unknown
-
2001
- 2001-06-15 CA CA002411553A patent/CA2411553A1/en not_active Abandoned
- 2001-06-15 JP JP2002503291A patent/JP2003535897A/ja active Pending
- 2001-06-15 AU AU2001274765A patent/AU2001274765B2/en not_active Ceased
- 2001-06-15 KR KR1020027017396A patent/KR100692235B1/ko not_active IP Right Cessation
- 2001-06-15 DK DK01941408T patent/DK1307192T3/da active
- 2001-06-15 CN CNB018142788A patent/CN1250218C/zh not_active Expired - Fee Related
- 2001-06-15 ES ES01941408T patent/ES2257416T3/es not_active Expired - Lifetime
- 2001-06-15 IL IL15315801A patent/IL153158A0/xx not_active IP Right Cessation
- 2001-06-15 CN CNA2006100088164A patent/CN1846697A/zh active Pending
- 2001-06-15 EP EP01941408A patent/EP1307192B1/de not_active Expired - Lifetime
- 2001-06-15 DE DE60117541T patent/DE60117541T2/de not_active Expired - Lifetime
- 2001-06-15 NZ NZ523048A patent/NZ523048A/en not_active IP Right Cessation
- 2001-06-15 US US10/311,760 patent/US7872035B2/en not_active Expired - Fee Related
- 2001-06-15 WO PCT/SE2001/001379 patent/WO2001097807A1/en active IP Right Grant
- 2001-06-15 AT AT01941408T patent/ATE318597T1/de active
- 2001-06-15 PT PT01941408T patent/PT1307192E/pt unknown
- 2001-06-15 BR BR0111900-1A patent/BR0111900A/pt not_active IP Right Cessation
- 2001-06-15 AU AU7476501A patent/AU7476501A/xx active Pending
- 2001-06-15 EP EP05028367A patent/EP1656940A1/de not_active Withdrawn
- 2001-06-15 MX MXPA02012574A patent/MXPA02012574A/es active IP Right Grant
-
2002
- 2002-11-28 IL IL153158A patent/IL153158A/en unknown
- 2002-12-05 ZA ZA200209902A patent/ZA200209902B/en unknown
- 2002-12-18 NO NO20026085A patent/NO330300B1/no not_active IP Right Cessation
-
2003
- 2003-08-19 HK HK03105920A patent/HK1053609A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
NO20026085D0 (no) | 2002-12-18 |
ES2257416T3 (es) | 2006-08-01 |
DE60117541T2 (de) | 2006-09-14 |
CA2411553A1 (en) | 2001-12-27 |
IL153158A0 (en) | 2003-06-24 |
KR100692235B1 (ko) | 2007-03-09 |
AU7476501A (en) | 2002-01-02 |
US20040092563A1 (en) | 2004-05-13 |
WO2001097807A1 (en) | 2001-12-27 |
ATE318597T1 (de) | 2006-03-15 |
ZA200209902B (en) | 2004-03-05 |
EP1307192A1 (de) | 2003-05-07 |
EP1307192B1 (de) | 2006-03-01 |
CN1447693A (zh) | 2003-10-08 |
US7872035B2 (en) | 2011-01-18 |
CN1250218C (zh) | 2006-04-12 |
CN1846697A (zh) | 2006-10-18 |
SE0002353D0 (sv) | 2000-06-22 |
KR20030019444A (ko) | 2003-03-06 |
EP1656940A1 (de) | 2006-05-17 |
DK1307192T3 (da) | 2006-06-12 |
PT1307192E (pt) | 2006-06-30 |
NO20026085L (no) | 2002-12-18 |
AU2001274765B2 (en) | 2005-08-18 |
NO330300B1 (no) | 2011-03-28 |
MXPA02012574A (es) | 2003-04-10 |
HK1053609A1 (en) | 2003-10-31 |
BR0111900A (pt) | 2003-05-13 |
JP2003535897A (ja) | 2003-12-02 |
NZ523048A (en) | 2004-09-24 |
IL153158A (en) | 2008-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20050851L (no) | Kaspase-inhibitorer og anvendelser derav | |
DE60316779D1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
GB0005251D0 (en) | Therapeutic compounds | |
ATE443043T1 (de) | Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer | |
BR0212042A (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto | |
WO2005013894A3 (en) | Benzodiazepine cgrp receptor antagonists | |
ATE302751T1 (de) | Verbindungen zur behandlung der alzheimerischen krankheit | |
JO2371B1 (en) | 4-phenyl-pyridine derivatives | |
WO2002002520A3 (en) | Compounds to treat alzheimer's disease | |
NO20093464L (no) | Nye medikamentblandinger basert pa anti-cholinergisk effektive forbindelser og beta-mimetika | |
GB0223040D0 (en) | Therapeutic compounds | |
DE69507029D1 (de) | Pharmazeutische zusammensetzungen enthaltend einen opiat antagonist und calcium salze, ihre verwendung zur behandlung von endorphin-vermittelten krankheiten | |
DE60209511D1 (de) | Zusammensetzungen zur behandlung des schnupfens, welche ipratropium und xylometazolin enthalten | |
ATE396174T1 (de) | Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten | |
WO2005000807A3 (en) | Benzodiazepine cgrp receptor antagonists | |
CA2378613A1 (en) | Selective iglur5 receptor antagonists for the treatment of migraine | |
IS2613B (is) | Útskipt díketópíperasín sem oxýtósínblokkar | |
ATE369348T1 (de) | Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie | |
DE60117541D1 (de) | Candesartan zur Behandlung von Migräne | |
SE0203349D0 (sv) | New use | |
DE50214537D1 (de) | C2-disubstituierte indan-1-one und ihre derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
ATE353221T1 (de) | Verwendung von gegen candida wirksamen mitteln zur behandlung von störungen der oralen und intestinalen mucosa | |
SE9901273D0 (sv) | Novel compounds | |
FR2804867B1 (fr) | Application de derives de xanthine pour la preparation d'un medicament destine a la prevention ou au traitement de l'osteoporose |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |